Latest filing published 14 Feb 2024 for Kyverna Therapeutics, Inc., €12k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -89.8%Entry US$29.75 · Close at T+365 US$3.03
- +62.3%Entry US$336.42 · Close at T+365 US$546.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Vida Ventures, LLC: trading record in brief
Vida Ventures, LLC has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Kyverna Therapeutics, Inc., Oyster Point Pharma, Inc. and Q32 Bio Inc. In total, 7 filings cover trades dated from 2 April 2018 to 12 February 2024.
Purchases make up the whole of the open-market record (4 purchases, €12.7M). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2024: 2 purchases and no sales on the market.
In size, the median ticket on the buying side is €3.8M. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 3 purchases show a median change of -46.7%, with the price up in 33% of them. These figures describe past trades and do not predict future prices.
The latest filing, published on 14 February 2024, reports an open-market purchase of €12k in Kyverna Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Vida Ventures, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 583 shares@ US$22.000.2% of flowCommon StockSEC:0000950170-24-015479:2Canonical exit: 12 May 2024 (T+90)
- 252,553 shares@ US$22.0099.8% of flowCommon StockSEC:0000950170-24-015479:1Canonical exit: 12 May 2024 (T+90)
- 4,523,924 sharesCommon StockSEC:0000950170-24-015479:0
- 778,468 sharesCommon Stock, par value $0.001 per shareSEC:0001104659-19-059645:0
- 185,000 shares@ US$16.00100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001104659-19-059645:1Canonical exit: 2 Feb 2020 (T+90)
- 395,845 shares0Common StockSEC:0000899243-18-009441:0
- 375,000 shares@ US$16.00100.0% of flowCommon StockSEC:0000899243-18-009441:1Canonical exit: 1 Jul 2018 (T+90)
7 of 7 declarations
